Substance / Medication

Goserelin

SNOMED 108771008 UMLS C0120107

Overview

Active Ingredient

goserelin

RxNorm CUI

50610

Indications & Related Conditions

Conditions associated via SNOMED clinical relationships

Malignant tumour of prostate

Administration & Protocol

Dosing, route, and treatment protocol

Administration details including route, dosing schedules, preparation instructions, and contraindications are pending physician authorship.

Monitoring & Follow-Up

Biomarkers relevant to this intervention via related conditions

Prostate specific Ag

LOINC 2857-1

primary

Clinical Trials

11 trials linked to this intervention

Total Trials

Recruiting

With Results

Recent Trials

A Study to Assess the Bioequivalence of Follitropin Alfa Solution in Pen and Follitropin Alfa Powder in Vial in Healthy Downregulated Male Participants

NCT07097259Phase 1Completed55 enrolled

Finite Androgen Ablation With or Without Abiraterone Acetate and Prednisone in Treating Patients With Recurrent Prostate Cancer

NCT01786265Phase 2Active Not Recruiting310 enrolled

Phase IIIb Study of Ribociclib + ET in Early Breast Cancer

NCT05827081Phase 3Recruiting1400 enrolled

Effect of a GnRH Analog on Hepatic Steatosis

NCT06523530Phase 4Recruiting62 enrolled

Roll-over Study to Allow Continued Access to Ribociclib

NCT05161195Phase 4Active Not Recruiting134 enrolled

View all 11 trials on ClinicalTrials.gov

Research Evidence

Published studies and systematic reviews

Sort:

Degarelix versus goserelin plus bicalutamide therapy for lower urinary tract symptom relief, prostate volume reduction and quality of life improvement in men with prostate cancer: a systematic review and meta-analysis.

Cui Yuanshan, Zong Huantao, Yan Huilei et al. · Urol Int · 2014

PMID: 24603064Meta-Analysis

Twenty-Year Benefit From Adjuvant Goserelin and Tamoxifen in Premenopausal Patients With Breast Cancer in a Controlled Randomized Clinical Trial.

Johansson Annelie, Dar Huma, van 't Veer Laura J et al. · J Clin Oncol · 2022

PMID: 35862873RCTFull text (PMC)

The affect of goserelin on the QoL of women having chemotherapy for EBC: Results from the OPTION trial.

R Leonard, A Yellowlees, J Mansi et al. · Breast · 2020

PMID: 32505861RCTFull text (PMC)

Neoadjuvant androgen deprivation therapy for prostate volume reduction, lower urinary tract symptom relief and quality of life improvement in men with intermediate- to high-risk prostate cancer: a randomised non-inferiority trial of degarelix versus goserelin plus bicalutamide.

Mason M, Maldonado Pijoan X, Steidle C et al. · Clin Oncol (R Coll Radiol) · 2013

PMID: 23257248RCT

Goserelin and bicalutamide treatments alter the expression of microRNAs in the prostate.

Lehmusvaara Saara, Erkkilä Timo, Urbanucci Alfonso et al. · Prostate · 2013

PMID: 22674191RCT

Combined effects of goserelin and tamoxifen on estradiol level, breast density, and endometrial thickness in premenopausal and perimenopausal women with early-stage hormone receptor-positive breast cancer: a randomised controlled clinical trial.

Yang H, Zong X, Yu Y et al. · Br J Cancer · 2013

PMID: 23860520RCTFull text (PMC)

A comparative study of the effect of raloxifene and gosereline on uterine leiomyoma volume changes and estrogen receptor, progesterone receptor, bcl-2 and p53 expression immunohistochemically in premenopausal women.

Baytur Yesim Bulbul, Ozbilgin Kemal, Cilaker Serap et al. · Eur J Obstet Gynecol Reprod Biol · 2007

PMID: 16973256RCT

Luteinizing hormone release after administration of the gonadotropin-releasing hormone agonist Fertilan (goserelin) for synchronization of ovulation in pigs.

Brüssow K-P, Schneider F, Tuchscherer A et al. · J Anim Sci · 2007

PMID: 17179548RCT

Administration of goserelin acetate after uterine artery embolization does not change the reduction rate and volume of uterine myomas.

Vilos George A, Vilos Angelos G, Abu-Rafea Basim et al. · Fertil Steril · 2006

PMID: 16579996RCT

Real-world effectiveness and safety of goserelin 10.8-mg depot in Chinese patients with localized or locally advanced prostate cancer.

Chen Nanhui, Wang Zengjun, Chen Ming et al. · Cancer Biol Med · 2024

PMID: 38318809ObservationalFull text (PMC)

Research data from MEDLINE/PubMed

Benefits & Expected Outcomes

Benefits, expected outcomes, efficacy data, and NNT (Number Needed to Treat) are pending physician authorship and evidence review.

Risks & Side Effects

Risk profile, common and serious adverse effects, contraindications, and drug interactions are pending physician authorship.

Related Symptoms

Symptoms associated with conditions this intervention addresses

No related symptoms have been mapped yet. Symptom linkages are derived through associated conditions.

Alternatives & Comparisons

Alternative treatments, comparison data, and clinical decision support are pending physician authorship.

Medical Disclaimer

This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider regarding any medical condition or treatment plan.

Do not start, stop, or change any treatment without consulting your healthcare provider.

Specialists

Providers who commonly manage this intervention

Medical Oncology Physician

Internal Medicine — Medical Oncology

Urology

Health Goals

Goals connected through associated conditions

Screen for Cancer Risk

Quick Facts

Type: Substance / Medication
Fully Specified Name: Goserelin (substance)
SNOMED CT: 108771008
UMLS CUI: C0120107
RxNorm CUI: 50610

Clinical Data

This intervention maps to 5 entities in the Ltrl knowledge graph.

Conditions

Biomarkers

Specialists

Symptoms

Clinical Trials

Data is sourced from SNOMED CT, UMLS, and the Ltrl clinical knowledge graph. Content sections marked as pending require physician authorship. Consult a healthcare provider before starting any treatment.